Citations

Clear

34 citation(s) found for "Schenk, Ed".

Abstract Wed136: Integration of Mechanistic Fontan Circulatory Models with Interpretable Machine Learning Classifiers
Schenk, Noah A. , Egbe, Alexander , Beard, Daniel , Carlson, Brian E.

Mayo Clinic

Circulation Research | October 8, 2025 | Volume: 137 | Issue: Suppl_1 | Pages: No page available

10.1161/res.137.suppl_1.wed136 Get It

Introduction/Background: Despite numerous medical advances, 30% of patients with Fontan circulation require heart transplantation by 21. Current risk stratification relies on clinical metrics that lack strong correlations to patient outcomes, leading to a high waitlist mortality. Hypothesis: Integration of physics-based hemodynamic modeling with interpretable machine learning will improve prediction of patient outcomes (listing for heart transplant and/or cardiac death) by quantifying physiologic mechanisms inaccessible through clinical measures alone. Goals/Aims: 1. Develop a lumped-parameter mechanistic model (LPMM) of Fontan circulation 2. Identify patient clusters and predictors of patient outcomes 3. Validate model-informed classifiers against clinical-only approaches Methods/Approach: A LPMM incorporating ventricular sarcomere mechanics, atrial hemodynamics, and vascular viscoelastic effects was optimized to cardiac catheterization and echocardiography data from 51 patients (age 25±8 years). Thirty-eight parameters (ventricular inotropy, atrial stiffness, pulmonary elastance, etc.) were calibrated via surrogate optimization, minimizing least-squares error versus 11 clinical targets. Partial least-squares regression with leave-one-out cross-validation compared clinical-only versus model-informed classifiers of outcomes. Results/Data: The LPMM achieved 2% mean error across hemodynamic targets, with CVP and pulmonary pressures matching clinical measurements within 1%. Model-derived minimum atrial pressure (4.46±1.78 vs 2.68±0.87 mmHg, p<0.05) outperformed all clinical variables in discriminating patient outcomes. Integration of LPMM parameters increased AUROC from 0.67 to 0.78 for patient outcome prediction. Conclusions: Physics-based modeling identifies ventricular passive stiffness, atrial end-diastolic volume, and minimum atrial pressure, along with patient age (a clinical value) as critical determinants of Fontan failure. Combined mechanistic-machine learning approaches enable phenotype-specific risk stratification, supporting earlier referral for advanced therapies. This methodology establishes a framework for precision management of complex congenital circulations.
KRAS Promotes GLI2-Dependent Transcription during Pancreatic Carcinogenesis
Sigafoos, Ashley N. , Tolosa, Ezequiel J. , Carr, Ryan M. , Fernández‐Barrena, Maite G. , Almada, Luciana L. , Pease, David R. , Hogenson, Tara L. , Arul, Glancis L. Raja , Mousavi, Fatemeh , Sen, Sandhya , Vera, Renzo E., Marks, David L. , Flores, Luis F. , LaRue-Nolan, Kayla C. , Wu, Chen , Vrabel, Anne M., Sicotte, Hugues , Smyrk, Thomas C. , Zhang, Lizhi , Oberg, Ann L. , Elsawa, Sherine F. , Pin, Christopher L. , Mao, Junhao , Fernández-Zapico, Martín E. , Raja Arul, Glancis L, Bamlet, William R , Sicotte, Hugues , Schenk, Erin L. , Chaffee, Kari G. , Oberg, Ann L , Chevet, Eric , Graham, Rondell P , Hagen, Catherine E , McWilliams, Robert R , Fernandez-Zapico, Martin E , Elsawa, Sherine F , Raja Arul, Glancis Luzeena , Carr, Ryan M , Bamlet, William R. , Rabe, Kari G. , Zaphiropoulos, Peter G. , Chevet, Éric , Graham, Rondell P. , Hagen, Catherine E. , Magliano, Marina Pasca di , McWilliams, Robert R.

Mayo Clinic

Cancer Research Communications | June 19, 2024 | Volume: 4 | Issue: 7 | Pages: 1677-1689

10.1158/2767-9764.crc-23-0464 | PMID 38896052 Get It

Abstract Aberrant activation of GLI transcription factors has been implicated in the pathogenesis of different tumor types including pancreatic ductal adenocarcinoma. However, the mechanistic link with established drivers of this disease remains in part elusive. In this study, using a new genetically engineered mouse model overexpressing constitutively active mouse form of GLI2 and a combination of genome-wide assays, we provide evidence of a novel mechanism underlying the interplay between KRAS, a major driver of pancreatic ductal adenocarcinoma development, and GLI2 to control oncogenic gene expression. These mice, also expressing KrasG12D, show significantly reduced median survival rate and accelerated tumorigenesis compared with the KrasG12D only expressing mice. Analysis of the mechanism using RNA sequencing demonstrate higher levels of GLI2 targets, particularly tumor growth–promoting genes, including Ccnd1, N-Myc, and Bcl2, in KrasG12D mutant cells. Furthermore, chromatin immunoprecipitation sequencing studies showed that in these cells KrasG12D increases the levels of trimethylation of lysine 4 of the histone 3 (H3K4me3) at the promoter of GLI2 targets without affecting significantly the levels of other major active chromatin marks. Importantly, Gli2 knockdown reduces H3K4me3 enrichment and gene expression induced by mutant Kras. In summary, we demonstrate that Gli2 plays a significant role in pancreatic carcinogenesis by acting as a downstream effector of KrasG12D to control gene expression.
Impact of NEOD001 on Neuropathy in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction: Results From the Expansion Phase of a Phase 1/2 Study (S5.001)
Liedtke, Michaela , Comenzo, Raymond L. , Landau, Heather , Weiss, Brendan M. , Zonder, Jeffrey A. , Walling, Jackie , Kinney, Gene G. , Koller, Martin, Schenk, Dale B., Guthrie, Spencer , Liu, Enchi , Sanchorawala, Vaishali , Gertz, Morie A.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 88 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.88.16_supplement.s5.001 Get It

660 Clinicopathologic characteristics of patients with metastatic colorectal cancer with molecular responses following treatment with an individualized neoantigen vaccine regimen
Liao, Chih‐Yi , Henick, Brian S. , Overman, Michael J. , Polite, Blasé N. , Roychowdhury, Sameek , Ahn, Daniel H. , Johnson, Melissa M., Schenk, Desiree, Bae, Kyounghwa, Jooss, Karin , Johnson, Benny , Spira, Alexander I. , Carbone, David Paul , Mahipal, Amit , Johnson, Melissa, Davis, Matthew M. , Ferguson, Andrew, Solomon, Benjamin

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A691-A691

10.1136/jitc-2022-sitc2022.0660 Get It

Tumor Microenvironment CD14+ Cells Correlate with Poor Overall Survival in Patients with Early-Stage Lung Adenocarcinoma
Withers, Sarah G., Bulur, Peggy A. , Dietz, Allan B. , Boland, Jennifer M. , Dietz, Allan B , Schenk, Erin L.

Mayo Clinic

Cancers | September 18, 2022 | Volume: 14 | Issue: 18 | Pages: 4501

10.3390/cancers14184501 | PMID 36139660 Get It

Patients with early-stage lung adenocarcinoma have a high risk of recurrent or metastatic disease despite undergoing curative intent therapy. We hypothesized that increased CD14+ cells within the tumor microenvironment (TME) could stratify patient outcomes. Immunohistochemistry for CD14 was performed on 189 specimens from patients with lung adenocarcinoma who underwent curative intent surgery. Outcomes and associations with clinical and pathologic variables were determined. In vitro studies utilized a coculture system to model the lung cancer TME containing CD14+ cells. Patients with high levels of TME CD14+ cells experienced a median overall survival of 5.5 years compared with 8.3 and 10.7 years for those with moderate or low CD14 levels, respectively (p < 0.001). Increased CD14+ cell tumor infiltration was associated with a higher stage at diagnosis and more positive lymph nodes at the time of surgery. This prognostic capacity remained even for patients with early-stage disease. Using an in vitro model system, we found that CD14+ cells reduced chemotherapy-induced cancer cell death. These data suggest that CD14+ cells are a biomarker for poor prognosis in early-stage lung adenocarcinoma and may promote tumor survival. CD14+ cell integration into the lung cancer TME can occur early in the disease and may be a promising new therapeutic avenue.
Liver Transplantation as a New Standard of Care in Patients With Perihilar Cholangiocarcinoma? Results From an International Benchmark Study
Breuer, Eva , Doyle, Majella B. , Yang, Liu , Anwar, Imran J. , Merani, Shaheed , Limkemann, Ashley , Jeddou, Heithem , Kim, Steven C. , Nassar, Ahmed , Vibert, Éric , Oliveira, Michelle, Cherqui, Daniel , Porte, Robert J. , Magliocca, Joseph F. , Fischer, Lutz , Zieniewicz, Krzysztof , Ramı́rez, Pablo , Foley, David P. , Langnas, Alan N. , Polak, Wojciech G. , Rosen, Charles B. , Dutkowski, Philipp , Clavien, Pierre‐Alain , Chapman, William C. , Taner, C. Burcin , Clavien, Pierre-Alain , Chapman, William C , Polak, Wojciech G , Mueller, Matteo , Murad, Sarwa Darwish , López‐López, Víctor , Hoogwater, Frederik J.H. , Fondevila, Constantino , Boudjéma, Karim , Schenk, Austin D. , Knechtle, Stuart J. , Chapman, William C. , Gores, Gregory J. , Heimbach, Julie K. , Yang, Liu

Mayo Clinic

Annals of Surgery | July 27, 2022 | Volume: 276 | Issue: 5 | Pages: 846-853

10.1097/sla.0000000000005641 | PMID 35894433 Get It

Objective: To define benchmark values for liver transplantation (LT) in patients with perihilar cholangiocarcinoma (PHC) enabling unbiased comparisons. Background: Transplantation for PHC is used with reluctance in many centers and even contraindicated in several countries. Although benchmark values for LT are available, there is a lack of specific data on LT performed for PHC. Methods: PHC patients considered for LT after Mayo-like protocol were analyzed in 17 reference centers in 2 continents over the recent 5-year period (2014–2018). The minimum follow-up was 1 year. Benchmark patients were defined as operated at high-volume centers (≥50 overall LT/year) after neoadjuvant chemoradiotherapy, with a tumor diameter <3 cm, negative lymph nodes, and with the absence of relevant comorbidities. Benchmark cutoff values were derived from the 75th to 25th percentiles of the median values of all benchmark centers. Results: One hundred thirty-four consecutive patients underwent LT after completion of the neoadjuvant treatment. Of those, 89.6% qualified as benchmark cases. Benchmark cutoffs were 90-day mortality ≤5.2%; comprehensive complication index at 1 year of ≤33.7; grade ≥3 complication rates ≤66.7%. These values were better than benchmark values for other indications of LT. Five-year disease-free survival was largely superior compared with a matched group of nodal negative patients undergoing curative liver resection (n=106) (62% vs 32%, P<0.001). Conclusion: This multicenter benchmark study demonstrates that LT offers excellent outcomes with superior oncological results in early stage PHC patients, even in candidates for surgery. This provocative observation should lead to a change in available therapeutic algorithms for PHC.
A phase 1a dose-escalation study of PY314, a TREM2 (Triggering Receptor Expressed on Macrophages 2) targeting monoclonal antibody.
Patnaik, Amita , Tan, Winston , Jahchan, Nadine S. , Pierce, Kristen J. , Li, Yunfeng , Reyno, Len, Chamberlain, Marc C. , Hamilton, Erika , Winer, Ira Seth , Hubbard, Joleen M. , Schenk, Erin L. , Sonbol, Mohamad Bassam , Pierce, Kristen

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 2648-2648

10.1200/jco.2022.40.16_suppl.2648 Get It

2648 Background: To characterize the safety and tolerability of PY314, an immunosuppressive macrophage depleting antibody, as a single agent and in combination with pembrolizumab in subjects with advanced refractory solid tumors including subject’s refractory to checkpoint inhibitors if approved for that indication. Methods: Two were evaluated in subjects with advanced solid tumors, single agent PY314 and PY314 in combination with 200 mg of pembrolizumab using a 3+3 dose escalation study design. Dosing was intravenous and administered once every 3-weeks, a defined cycle. Disease assessment by RECIST 1.1 was performed every 6 weeks. Each stratum included 4 dose levels of PY314 (1, 3, 10, and 20 mg/kg). Pharmacokinetics were evaluated at specified time points. Archival tumor tissue was analyzed for TREM2 expression by immunohistochemistry. Based on preclinical evaluation of TREM2 expression, HR+ HER2- and triple negative breast cancer, colorectal cancer, renal cell cancer, non-small cell lung cancer and gynecologic cancers were studied. Results: 28 subjects (median age 60 years [range 26-76], 22 females and 6 ) with an ECOG PS <2 were enrolled and all, but one was (1 subject withdrew consent after dosing). 15 subjects were treated with single agent PY314 and 13 were treated with the combination. No infusion-related reactions, dose limiting toxicities, suspected unexpected serious adverse reactions or high-grade treatment related adverse events (TRAEs) that resulted in treatment discontinuance was seen. 12 subjects experienced at least one TRAE, and in all but one subject, these were low grade. One subject experienced a treatment-related immune system disorder. serious adverse events, all unrelated to treatment. TREM2 expression in archival tumor ranged from 0.0-20%. PY314 pharmacokinetics were linear, dose proportional, unaffected by concomitant pembrolizumab and with a half-life of 8-9 days. Best radiographic response was stable disease seen in 11 subjects (39.3%) ranging in duration from 9-42 weeks. 6 subjects with stable disease have progressed and 5 remain on treatment. Conclusions: PY314 was well tolerated and has an excellent safety profile both as a single agent and in combination with pembrolizumab. A recommended dose for expansion was derived and enrollment in five prespecified cancers is ongoing. Clinical trial information: 04691375.
Duration of pemetrexed maintenance therapy with or without pembrolizumab is associated with risk of renal toxicity in patients with metastatic nonsquamous NSCLC.
Nie, Yunan , Pacheco, Jose M., Purcell, W. Thomas, Bunn, Paul A. , Camidge, D. Ross , Patil, Tejas , Hu, Junxiao , Schenk, Erin L.

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: e21205-e21205

10.1200/jco.2021.39.15_suppl.e21205 Get It

e21205 Background: Use of maintenance pemetrexed with pembrolizumab is the standard of care among patients with metastatic nonsquamous NSCLC without EGFR or ALK alterations treated with the KEYNOTE-189 regimen. Whether the addition of pembrolizumab to pemetrexed maintenance alters the risk of renal toxicity is not well characterized. Methods: A single center retrospective study was performed. The frequency of acute kidney injury as well as the rates of discontinuation due to renal injury was assessed. Acute renal injury was defined as ≥ 0.3 increase in serum creatinine (sCr) above the upper limit of normal or a rise in sCr ≥ 1.5 times baseline per KDIGO criteria. A Fisher exact test was conducted to compare the rate of renal injury between the two groups. Logistic regression adjusting for performance status, prior lines of treatment, and number of maintenance cycles was performed. Results: We identified 114 patients who received either maintenance pemetrexed or pemetrexed + pembrolizumab. The median number of cycles for the maintenance pemetrexed and pemetrexed + pembrolizumab groups was 5 and 7 cycles respectively. Of these, 41% (47/114) patients developed acute renal injury during their treatment course. Renal injury was seen in 14.3% (5/35) patients who received single agent pemetrexed maintenance and 25% (3/12) who received maintenance pemetrexed + pembrolizumab with no significant difference in the rates of renal injury between both arms (p = 0.403). Among patients who developed acute renal injury, 9% (4/47) permanently discontinued maintenance due to nephrotoxicity. All patients who permanently discontinued therapy received maintenance pemetrexed alone. When adjusting for covariates, ECOG performance status and number of prior lines of therapy did not increase the risk of renal toxicity. Logistic regression analysis identified that the rate of renal injury was significantly associated with the number of maintenance cycles received (p-value = 0.017, OR = 1.14, 95% CI 1.03 - 1.29). The odds of developing renal injury were 1.14 times higher with each additional cycle of maintenance therapy received. Conclusions: Renal injury is common among patients treated with patients receiving maintenance therapy. The addition of pembrolizumab to maintenance pemetrexed did not significantly increase the rate of renal injury. The risk of renal injury appears to correlate with the total number of maintenance cycles received suggesting a cumulative risk of nephrotoxicity over time.
Effect of continuing osimertinib with chemotherapy in the post-progression setting on progression-free survival among patients with metastatic epidermal growth factor receptor (EGFR) positive non-small cell lung cancer.
Tsui, David Chun Cheong, Purcell, W. Thomas, Bunn, Paul A. , Pacheco, Jose M., Camidge, D. Ross , Patil, Tejas , Nicklawsky, Andrew , Schenk, Erin L.

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: 9124-9124

10.1200/jco.2021.39.15_suppl.9124 Get It

9124 Background: Continuing a 1st generation EGFR TKI with chemotherapy upon TKI progression was not shown to be beneficial in the IMPRESS trial. However, the validity of this approach with osimertinib remains under explored. We attempted to characterize the efficacy of continuing osimertinib with chemotherapy in the post-progression setting. Methods: A single-center retrospective review of patients with metastatic EGFR mutant NSCLC who had progressed on osimertinib was performed. Clinical characteristics and treatment outcomes were noted. Progression free survival (PFS), duration of treatment (DOT), overall survival (OS) and rates of intracranial progression were captured. ANOVA or a Fisher exact test were used to identify associations between cohort characteristics and treatment outcomes. Differences in PFS, DOT and OS were assessed using a log-rank test. A Cox proportional hazard model was used to adjust for potential confounders. Results: 73 patients with EGFR mutant NSCLC with post-osimertinib treatment outcomes were identified. Cohort characteristics are summarized in Table. Median duration of follow up was 41 months. Upon progression, osimertinib was discontinued in 34 patients (Cohort A) and continued with next line of therapy in 39 patients (Cohort B). Survival analyses were adjusted for prior lines of therapy, use of platinum doublet chemotherapy, and use of immune checkpoint inhibitors in the post-progression setting. After adjusting for covariates, continuing osimertinib post-progression was associated with an improved PFS (7 vs 4 months; HR 0.58; 95% CI 0.34 – 1.00; p = 0.003) and DOT (7 vs 4 months; HR 0.52; 95% CI 0.31 – 0.87; p = 0.006). There was no difference in OS between Group A and B (52 vs 41 months; HR 0.73; 95% CI 0.43 – 1.24; p = 0.234). Rates of intracranial progression were similar between Group A and B (28% vs 23%; p = 0.649). Conclusions: After adjusting for covariates, continuing osimertinib with chemotherapy in the post-progression setting was associated with a significant difference in PFS and DOT, but with no differences in OS. Continuing osimertinib does not appear to influence the rate of subsequent intracranial progression. Prospective studies are needed to identify the optimal practice pattern.[Table: see text]
Diagnostic Yield of Neck CT Angiography in Young Adults With Anterior Circulation Ischemic Stroke: A Community Based Study
Schenk, William B., Brinjikji, Waleed , Larson, Anthony S. , Nasr, Deena M. , Larson, Anthony

Mayo Clinic

The Neurohospitalist | November 24, 2020 | Volume: 11 | Issue: 2 | Pages: 119-124

10.1177/1941874420974542 | PMID 33791054 Get It

Background and Purpose: Few community-based studies investigating young adult strokes exist. The aim of this study was to determine the diagnostic yield of head and neck CTA in evaluation of anterior circulation ischemic stroke in young adults. Materials and Methods: This retrospective review is limited to patients between the ages of 18-50 presenting to the Mayo Clinic Rochester emergency department or referred from smaller institutions in adjacent counties. Patients with posterior circulation infarcts, amaurosis fugax, central retinal artery occlusion or transient ischemic attacks were excluded. The presence of carotid dissection, webs, plaque, or other high-risk lesions were recorded. Results: A total of 136 patients met inclusion criteria. Mean degree of carotid stenosis ipsilateral to infarct was 14.1%, compared to 6.5% on the contralateral side (p = .006). Ipsilateral mean carotid wall thickness measured .79 mm, compared to contralateral thickness of .80 mm (p = .51). Ipsilateral low-density plaque was observed in 22 patients (16.2%), and 21 patients (15.4%) on the contralateral side (p = .87). Ipsilateral calcified plaque was observed in 37 patients (27.2%), and 29 patients (21.3%) on the contralateral side (p = .31). 20 (14.7%) ipsilateral dissections were noted, compared to 4 (2.9%) contralateral dissections (p = .001). 3 (2.2%) ipsilateral carotid webs were identified, compared to 0 contralateral webs (p = .25). Conclusion: Carotid dissection was the most common cause of anterior circulation infarct identified on cervical CTA in this population. Carotid webs and atherosclerosis were not common findings.